Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Appointed CFO
Director departure
Appointed director
Notes underwriting agrmnt
|
|
ORAGENICS INC (OGEN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/29/2023 |
8-K
| Asset disposition |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF ORAGENICS, INC. CERTIFICATE OF DESIGNATION AND RIGHTS OF SERIES E MIRRORING PREFERRED STOCK Pursuant to Section 607.0602 of the Florida Business Corporation Act Oragenics, Inc., a corporation organized and existing under the laws of the State of Florida , does hereby certify: FIRST: That pursuant to authority conferred upon the Board of Directors of the Corporation by the Articles of Incorporation of the Corporation, as amended, the Board adopted the following resolutions on July 10, 2023 pursuant to the Corporation’ s Articles of Incorporation, as amended, and Sections 607.0602, 607.1002 and 607.1006 of the Florida Business Corporation Act, authorizing a new series of the Corporation’ s previously authorized Preferred Stock, no par val...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of August 4, 2023 , between Oragenics, Inc., a Florida corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, Common Stock and Series E Preferred Stock of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuab...",
"ORAGENICS, INC. ANNOUNCES PRIVATE PLACEMENT TAMPA, FL, – Oragenics, Inc. , biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement , an aggregate of 404,728 shares of the Company’ s common stock, $0.001 par value , and 404,728 shares of Series E Mirroring Preferred Stock . The Company intends to propose an amendment to its Amended and Restated Articles of Incorporation, in connection with the Company’ s annual meeting of shareholders, to effect an increase in the shares of Common Stock the Company is authorized to issue from 4,166,666 shares of Common Stock to 350,000,000 shares of Common Stock. The Series E Preferred..." |
|
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 04/14/2023 |
10-Q/A
| Quarterly Report for the period ended September 30, 2022 [amend] |
| 04/14/2023 |
10-Q/A
| Quarterly Report for the period ended June 30, 2022 [amend] |
| 04/14/2023 |
10-Q/A
| Quarterly Report for the period ended March 31, 2022 [amend] |
| 04/03/2023 |
8-K
| Investor presentation |
| 03/31/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/14/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/01/2023 |
8-K
| Quarterly results |
| 02/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/26/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/23/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...|
Docs:
|
"ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION ORAGENICS, INC. Oragenics, Inc. , does hereby certify that the Corporation’ s Articles of Incorporation originally filed with the Florida Department of State on November 6, 1996, as amended and restated on May 8, 2002, as further amended by those certain amendments filed October 28, 2009, September 22, 2010, August 30, 2011, June 2, 2014, January 10, 2017, May 8, 2017, November 7, 2017, November 9, 2017, December 29, 2017, January 16, 2018, June 21, 2018, July 13, 2018 and February 25, 2022 are hereby further amended pursuant to Section 607.1006 of the Florida Business Corporation Act of the State of Florida. The Corporation does hereby further certify that this amendment was duly adopted by the Corporation’ s Boar..." |
|
| 01/13/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 12/23/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split TAMPA, FL. – Oragenics, Inc. , a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that its Board of Directors on December 22, 2022 approved a 1-for-60 reverse stock split of the Company’ s issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the Company’ s authorized shares of common stock , such that, following the consummation of the Reverse Stock Split, the number of authorized shares of common stock will be reduced from 250,000,000 shares to 4,166,666 shares. As a result of the Reverse Stock Split, the Company’ s common stock is expected to begin trading on a split-adjusted basis when the markets open on January 23, 20..." |
|
| 12/22/2022 |
8-K
| Quarterly results |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/16/2022 |
8-K
| Quarterly results |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/31/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/03/2022 |
8-K
| Investor presentation |
| 09/30/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 09/30/2022 |
8-K
| Quarterly results |
|
|
|